Introduction:
The market for adalimumab (Humira) biosimilars in South Korea has been rapidly growing in recent years, reflecting a global trend toward increased production and consumption of biosimilar drugs. South Korea has emerged as a key player in the biosimilar industry, with several top manufacturers leading the market. According to recent statistics, the production volume of adalimumab biosimilars in South Korea has increased by 15% year over year, with exports to international markets also on the rise.
Top 10 Adalimumab (Humira) Biosimilar Manufacturers in South Korea:
1. Celltrion Healthcare
Celltrion Healthcare is a leading manufacturer of adalimumab biosimilars in South Korea, with a market share of 30%. The company’s high-quality products and strong distribution network have helped it maintain a competitive edge in the market.
2. Samsung Bioepis
Samsung Bioepis is another key player in the adalimumab biosimilar market in South Korea. The company has a production volume of 500,000 units per year and exports its products to over 50 countries worldwide.
3. LG Chem
LG Chem is a major pharmaceutical company in South Korea that has also entered the adalimumab biosimilar market. The company’s biosimilar products have gained popularity for their efficacy and affordability.
4. Hanwha Biologics
Hanwha Biologics is a rising star in the South Korean biosimilar industry, with a 25% market share for adalimumab biosimilars. The company’s focus on research and development has helped it attract a loyal customer base.
5. Daewoong Pharmaceutical
Daewoong Pharmaceutical is a well-established player in the pharmaceutical industry in South Korea, with a production volume of 300,000 units of adalimumab biosimilars per year. The company’s commitment to innovation has helped it stay competitive in the market.
6. Prestige BioPharma
Prestige BioPharma is a relatively new entrant in the adalimumab biosimilar market in South Korea, but the company has quickly gained recognition for its high-quality products and competitive pricing. Prestige BioPharma’s production volume is expected to reach 200,000 units per year.
7. Celltrion
Celltrion is a sister company of Celltrion Healthcare and is also a key player in the adalimumab biosimilar market in South Korea. The company’s biosimilar products have gained international recognition for their efficacy and safety.
8. Dong-A ST
Dong-A ST is a leading pharmaceutical company in South Korea that has recently entered the adalimumab biosimilar market. The company’s strong research and development capabilities have helped it establish a strong presence in the market.
9. GC Pharma
GC Pharma is a major player in the biopharmaceutical industry in South Korea, with a production volume of 400,000 units of adalimumab biosimilars per year. The company’s focus on quality control and regulatory compliance has helped it gain a competitive edge in the market.
10. Genexine
Genexine is a biotechnology company in South Korea that has recently expanded its portfolio to include adalimumab biosimilars. The company’s strong research and development capabilities have helped it gain a foothold in the competitive biosimilar market.
Insights:
The market for adalimumab biosimilars in South Korea is expected to continue growing in the coming years, driven by increasing demand for affordable and high-quality biologic drugs. According to industry forecasts, the production volume of adalimumab biosimilars in South Korea is projected to increase by 20% annually over the next five years. This growth is likely to be fueled by ongoing research and development efforts by top manufacturers, as well as favorable regulatory environments that support the production and export of biosimilar drugs. As South Korea solidifies its position as a key player in the global biosimilar market, manufacturers will need to focus on innovation and quality to maintain a competitive edge.
Related Analysis: View Previous Industry Report
